CA-VELODYNE-LIDAR
30.7.2020 14:02:16 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced that Emesent’s newly introduced Autonomy Level 2 (AL2) technology for Hovermap uses Velodyne lidar sensors to provide real-time perception and high-quality, accurate 3D data. Hovermap is a plug-and-play mapping and autonomy payload for industrial drones that enables autonomous flight in areas beyond visual line of sight (BVLOS) and without GPS connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200730005182/en/
The AL2 technology uses Velodyne’s Puck LITE lidar as the primary perception and mapping sensor. This allows autonomous exploration, navigation and lidar mapping in challenging inaccessible environments such as mines, civil construction works, telecommunications infrastructure and disaster response environments. As part of Emesent’s simultaneous localization and mapping (SLAM) based autonomy stack, AL2 powers drones to fly beyond communications range, self-navigate and avoid obstacles including thin wires and branches.
AL2 can be operated from take-off to landing by setting smart waypoints in a live 3D map streamed to a tablet. This allows operators to remain a safe distance from hazardous environments such as brows, stope edges, confined spaces and heights. The rich data from the Puck LITE sensor enables companies to gain better data insights on how to make mines and other environments safe.
“The Velodyne Puck LITE is simply a sensational sensor for creating drone-based mapping and autonomy solutions because of its compact size, light weight and performance – all critical for drone-mounted systems,” said Dr. Stefan Hrabar, Emesent CEO. “The sensor was an essential ingredient in helping us to create game-changing new technology that can obtain vital data in challenging environments in real time without risking the machine or operator safety.”
Emesent is an Automated with Velodyne partner at the forefront of GPS-denied drone autonomy. The company recently placed fourth in the urban circuit of the DARPA Subterranean (“SubT”) Challenge together with the Robotics and Autonomous Systems Group at the Commonwealth Scientific and Industrial Research Organization (CSIRO) and Georgia Institute of Technology.
“Emesent’s innovative use of Velodyne’s lidar sensors is helping to deliver valuable data and insights that were previously impossible to access,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “In addition to what they provide today to the mining, infrastructure, survey and mapping industries, it is exciting to consider how this innovation will help usher in a new era of autonomous drone operation across a variety of other industries.”
In the United States, the Federal Aviation Administration (FAA) currently has restrictions on drones flying beyond the visual line of sight. Emesent’s technology innovation could potentially usher in a new era of safe, autonomous drone flight – not only in mines but everywhere.
Velodyne Puck LITE sensors deliver a high-resolution image to measure and analyze indoor and outdoor environments. Designed for applications that require a sensor with a low weight and compact size, the Puck LITE delivers outstanding resolution and performance for mobile and UAV/drone applications. It provides a full 360-degree environmental view to deliver real-time 3D data.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Emesent
Emesent is a world-leader in drone autonomy, lidar mapping and data analytics. Founded in 2018, Emesent has since built a reputation for delivering high-quality data capture in the mining, infrastructure, survey and mapping industries. Their flagship product, Hovermap, is a smart mobile scanning unit that combines advanced collision avoidance and autonomous flight technologies to map hazardous and GPS-denied environments. Hovermap is uniquely versatile, it can be handheld, drone- or vehicle-mounted to map challenging, inaccessible areas. With a wide range of applications, Hovermap is being used by customers around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005182/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
